PATENT FOR SINUSITIS TREATMENT AWARDED

[Guest guest]

PATENT FOR SINUSITIS TREATMENT AWARDED

SinusPharma was issued a US patent last week for the treatment of

sinusitis, including chronic sinusitis, the leading chronic condition in

America impacting more than 32 million American adults annually.

Currently there is no FDA approved prescription or over the counter drug

labeled to treat chronic sinusitis.

The Company's new patent #6,576,224 relates to pharmaceutical

compositions comprised of anti-infective, anti-inflammatory and

mucolytic agents formulated for the treatment of sinusitis, particularly

by aerosol administration. SinusPharma refers to the unique formulations

underlying the patent issued today as its AdhesENT technology.

" SinusPharma's patented pharmaceutical compositions used with aerosol

administration represent the most innovative and technologically

advanced form of topical intranasal treatment available for patients who

historically were given medication in the oral form of pills or through

intravenous administration for stubborn or advanced sinus disease.

Aerosol therapy is believed to reduce systemic side effects generally

associated with oral and IV medication because it effectively targets

medication at the site of infection or inflammation rather than

systemically, " said Dr. Wahl, Chief of Otolaryngology at Scripps

Memorial Hospital, La Jolla, California.

Chronic sinusitis is the leading chronic condition in the United States.

Sinusitis, often referred to as sinus infection, occurs when the sinuses

become obstructed or inflamed, causing them to swell and block proper

drainage. Sufferers experience headaches, post-nasal drip, congestion,

fatigue, thick green and yellow mucus, and facial pain.

Sinusitis significantly impacts the cost of US healthcare, causing:

- 73 million restricted activity days in 1992

- 11.7 million doctor visits annually

- $5.8 billion estimated overall healthcare expenditures in 1996 alone

SinusPharma's mission is to become the world leader in providing

specialty pharmaceuticals and doctor/patient support services to help

sufferers of chronic sinus disorders. SinusPharma owns a portfolio of

intellectual property and has two wholly-owned subsidiaries,

SinusPharmacy Corporation and SinusPharmaceuticals Research Corporation.

Aerosol therapy is currently available by physician written prescription

through SinusPharmacy Corporation. SinusPharmacy's SinuNEB System

(http://www.sinuspharmacy.com/sinuneb.html) enables patients to breathe

in an aerosol mist of medication through their nose to topically treat

chronic sinus infections. Medications are specifically compounded based

on individual physician prescriptions using SinusPharma's patented

AdhesENT formulations.

SinusPharmaceuticals Research Corporation is a specialty pharmaceutical

company that seeks manufacturing and marketing approval from FDA for its

promising intellectual property portfolio of intranasal

topically-delivered AdhesENT drug formulations. SinusPharmaceuticals

believes that the eventual approval of such formulations by FDA will

inaugurate a new standard of care for treating sinusitis.

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/

[Guest guest]

> The Company's new patent #6,576,224 relates to pharmaceutical

> compositions comprised of anti-infective, anti-inflammatory and

> mucolytic agents formulated for the treatment of sinusitis

How do you find all these articles?

How are you feeling? We haven't heard from you in awhile.

jan